Axel Ullrich
| Axel Ullrich | |
|---|---|
| Born | Lauban, Silesia |
| Institutions | |
| Alma mater | |
| Known for | Sunitinib |
Axel Ullrich (born October 19, 1943 in Lauban, Silesia) is a German cancer researcher and has been the director of the molecular biology department at the Max Planck Institute of Biochemistry in Martinsried, Germany since 1988. This department's research has primarily focused on signal transduction. Ullrich has received Hamdan Award for Medical Research Excellence, awarded by Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, Dubai, United Arab Emirates in 2008 and Ullrich and his team received the Wolf Prize in 2010.
Ullrich received his primary degree in biochemistry at the University of Tübingen, Germany, he received a Ph.D. from the University of Heidelberg in Molecular Genetics in 1975. He did post-doctoral work at the University of California, San Francisco from 1975 to 1977 and worked as a senior scientist at Genentech in San Francisco, California from 1978 to 1988. From 1988, he has been at the Max Planck Institute of Biochemistry.
He was one of several scientific leaders of 200+ scientists in developing the anti-cancer drug Trastuzumab (trade name: Herceptin) at Genentech, and has co-founded five biotech companies, Axxima, U3 Pharma, Kinaxo, SUGEN (acquired by Pfizer) and Blackfield.
...
Wikipedia